AIM-listed med-tech firm ANGLE plc (LON:AGL,OTCQX:ANPCY) said its ground-breaking liquid biopsy outperformed the current tests used to tell whether a pelvic mass is malignant or benign.
Its Parsortix system was able to detect cancer in 95% of the cases, achieving a lower false positive rate than existing method of detection.
ANGLE’s technology was used in harness with a specially-developed algorithm using certain patient data.
Results came from a study of 400 people at two centres – Vienna and New York State.
ANGLE believes the Parsortix blood test has the potential to aid the diagnosis of ovarian cancer before a biopsy or surgery is performed.
Diagnosis before biopsy
Why does this matter? Well, it will allow those with disease to be referred directly to gynaecologic oncology surgeons.
At the same time, it should ensure patients with benign tumours are be cared for in their communities.
This streamlined strategy has the potential to cut costs and accelerate treatment.
ANGLE’s founder and chief executive said of the latest results: “This success enables ANGLE to move forward into the validation phase for the use of Parsortix in its first clinical application.
“We believe ANGLE is building momentum towards securing a leading and well differentiated commercial position in the emerging multi-billion dollar liquid biopsy market."
---adds CEO interview---